Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077423 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Y-mAbs Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT05077423 is a Phase 1 study that was terminated before completion, run by Y-mAbs Therapeutics. The registered enrollment target is 3 participants.
The verdict
NCT05077423, a Phase 1 study, was terminated before completion, sponsored by Y-mAbs Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Pediatric patients (\<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33\*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.
Interventions
- DRUG CD33*CD3 BsAb
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05077423
The ClinicalTrials.gov registry entry for NCT05077423 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Y-mAbs Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD33*CD3 BsAb is the first listed.
NCT05077423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05077423 about?
NCT05077423 is a clinical study titled "A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia". Pediatric patients (\<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33\*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.
What is the current status of trial NCT05077423?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2022-05-25. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT05077423?
The interventions under investigation include: CD33*CD3 BsAb (DRUG).
Who is sponsoring clinical trial NCT05077423?
This trial is sponsored by Y-mAbs Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.